A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo

Oncogene

Volumn 32, Issue 37, 2013, Pages 4406-4416

  Eberlein, C ^a   Kendrew, J ^a   McDaid, K ^a   Alfred, A ^b   Kang, J S ^b   Jacobs, V N ^a   Ross, S J ^a   Rooney, C ^a   Smith, N R ^a   Rinkenberger, J ^b   Cao, A ^a   Churchman, A ^c   Marshall, J F ^c   Weir, H M ^a   Bedian, V ^a   Blakey, D C ^a   Foltz, I N ^b   Barry, S T ^a  

^a ASTRAZENECA   (United Kingdom)

^b Amgen (Formerly Abgenix)   (Canada)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

vb6; vb8; beta 6; beta 8; Integrin; TGF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ALPHAVBETA8 INTEGRIN; BIOLOGICAL MARKER; FIBRONECTIN; GELATINASE B; HUMAN MONOCLONAL ANTIBODY; LATENCY ASSOCIATED PEPTIDE; MESSENGER RNA; MONOCLONAL ANTIBODY 264RAD; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CROSS REACTIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SKIN FIBROBLAST; STROMA CELL; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; FEMALE; HUMANS; INTEGRINS; LUNG NEOPLASMS; MACACA FASCICULARIS; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASMS; PROTEIN BINDING; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MACACA FASCICULARIS;

EID: 84884204893     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.460     Document Type: Article

References (49)

1. Sheppard D, Rozzo C, Starr L, Quaranta V, Erle DJ, Pytela R. Complete amino acid sequence of a novel integrin beta subunit (beta 6) identified in epithelial cells using the polymerase chain reaction. J Biol Chem 1990; 265: 11502-11507.
2. Busk M, Pytela R, Sheppard D. Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein. J Biol Chem 1992; 267: 5790-5796.
3. Yokosaki Y, Monis H, Chen J, Sheppard D. Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J Biol Chem 1996; 271: 24144-24150.
4. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-328.
5. DiCara D, Rapisarda C, Sutcliffe JL, Violette SM, Weinreb PH, Hart IR et al. Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem 2007; 282: 9657-9665.
6. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 1995; 108: 2241-2251.
7. Regezi JA, Ramos DM, Pytela R, Dekker NP, Jordan RC. Tenascin and beta 6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 2002; 38: 332-336.
8. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004; 45: 226-236.
9. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 2005; 115: 339-347.
10. Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem 2002; 50: 1371-1380.
11. Arihiro K, Kaneko M, Fujii S, Inai K, Yokosaki Y. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. Breast Cancer 2000; 7: 19-26.
12. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007; 67: 5889-5895.
13. Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, Meldrum CJ et al. Direct integrin alphavbeta6-ERK binding: implications for tumour growth. Oncogene 2002; 21: 1370-1380.
14. Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF. The integrin cytoplasmictail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. J Biol Chem 2004; 279: 26533-26539.
15. Al-Hazmi N, Thomas GJ, Speight PM, Whawell SA. The 120 kDa cell-binding fragment of fibronectin up-regulates migration of alphavbeta6-expressing cells by increasing matrix metalloproteinase-2 and -9 secretion. Eur J Oral Sci 2007; 115: 454-458.
16. Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001; 92: 641-650.
17. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE et al. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 2002; 23: 237-244.
18. Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, Violette S et al. HS1-associated protein X-1 regulates carcinoma cell migration and invasion via clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res 2007; 67: 5275-5284.
19. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, Thomas GJ. Alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. Cancer Res 2008; 68: 3295-3303.
20. Morgan MR, Jazayeri M, Ramsay AG, Thomas GJ, Boulanger MJ, Hart IR et al. Psoriasin (S100A7) associates with integrin b6 subunit and is required for avb6- dependent carcinoma cell invasion. Oncogene 2011; 30: 1422-1435.
21. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM et al. Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol 2007; 27: 4444-4453.
22. Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR et al. Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 2001; 117: 67-73.
23. Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 2004; 165: 723-734.
24. Thomas GJ, Hart IR, Speight PM, Marshall JF. Binding of TGF-beta1 latencyassociated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer 2002; 87: 859-867.
25. Popov Y, Patsenker E, Stickel F, Zaks J, Bhaskar KR, Niedobitek G et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008; 48: 453-464.
26. Ma LJ, Yang H, Gaspert A, Carlesso G, Barty MM, Davidson JM et al. Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 2003; 163: 1261-1273.
27. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008; 177: 56-65.
28. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008; 177: 82-90.
29. Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007; 170: 110-125.
30. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, Laurent GJ et al. Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006; 116: 1606-1614.
31. Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ et al. Thomas GJ, Weinreb PH, Fawell SE, Violette SM. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res 2008; 68: 561-570.
32. Mu D, Cambier S, Fjellbirkeland L, Baron JL, Munger JS, Kawakatsu H et al. The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1- MMP-dependent activation of TGF-beta1. J Cell Biol 2002; 157: 493-507.
33. Cambier S, Gline S, Mu D, Collins R, Araya J, Dolganov G, Einheber S et al. Integrin alpha(v)beta8-mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am J Pathol 2005; 166: 1883-1894.
34. Aluwihare P, Mu Z, Zhao Z, Yu D, Weinreb PH, Horan GS et al. Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J Cell Sci 2009; 122: 227-232.
35. Cambier S, Mu DZ, O'Connell D, Boylen K, Travis W, Liu WH et al. A role for the integrin alphavbeta8 in the negative regulation of epithelial cell growth. Cancer Res 2000; 60: 7084-7093.
36. Su H, Kim H, Pawlikowska L, Kitamura H, Shen F, Cambier S et al. Reduced expression of integrin alphavbeta8 is associated with brain arteriovenous malformation pathogenesis. Am J Pathol 2010; 176: 1018-1027.
37. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci USA 1996; 93: 7843-7848.
38. Ludbrook SB, Barry ST, Delves CJ, Horgan CM. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. Biochem J 2003; 369: 311-318.
39. Ryer EJ, Hom RP, Sakakibara K, Nakayama KI, Nakayama K, Faries PL et al. PKCdelta is necessary for Smad3 expression and transforming growth factor beta-induced fibronectin synthesis in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2006; 26: 780-786.
40. Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. implications for myofibroblast generation in breast neoplasia. Lab Invest 1993; 68: 696-707.
41. Mateu MG, Valero ML, Andreu D, Domingo E. Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-andmouth disease virus and effect on cell recognition. J Biol Chem 1996; 271: 12814-12819.
42. Kogelberg H, Tolner B, Thomas GJ, Di Cara D, Minogue S, Ramesh B et al. Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. J Mol Biol 2008; 382: 385-401.
43. Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI et al. Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest 2010; 120: 2842-2857.
44. Fleming YM, Ferguson GJ, Spender LC, Larsson J, Karlsson S, Ozanne BW et al. TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation. Oncogene 2009; 28: 983-993.
45. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R et al. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 2010; 16: 1191-1205.
46. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-b8. Oncogene 2011; 30: 806-821.
47. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2005; 344: 539-548.
48. Culhane AC, Quackenbush J. Confounding effects in 'A six-gene signature predicting breast cancer lung metastasis'. Cancer Res 2009; 69: 7480-7485.
49. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011; 17: 1514-1520.